2 Nickerson Street, Suite 101
17 articles with Visus Therapeutics
Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors
Visus Therapeutics Inc. today announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors.
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
9/28/2022A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval.
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
Visus Therapeutics Inc. today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics.
Visus Therapeutics, Inc. announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2022 Global Healthcare Conference on September 13th, 2022, at the InterContinental New York Barclay hotel.
Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia
Visus Therapeutics, Inc. and Zhaoke Ophthalmology Limited announced an exclusive licensing agreement for the development and commercialization of BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and select Southeast Asian territories.
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting
Visus Therapeutics Inc. today announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting , to be held May 1-4, 2022 in Denver, Colorado.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia
Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL ™ PF for the Treatment of Presbyopia.
Visus Therapeutics Announces Appointment of Eye Care Industry Veteran Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquarters
Visus Therapeutics Inc. today announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia.
Visus Therapeutics Appoints Ophthalmology Expert David Guyer, M.D., as Chairman of the Board and Welcomes Seasoned Life Sciences Executive Ted Danse as Head of Business Development
Visus Therapeutics Inc. today announced the appointment of ophthalmology and industry expert David Guyer, M.D. as the chairman of the Board
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.
Visus Therapeutics has acquired an additional $20 million in funding to support its mission of developing innovative ophthalmic therapies for people worldwide.
Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop
Visus Therapeutics Inc. today announced the close of a $36 million Series A Preferred Stock financing. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders